Integration event frequency of high-risk human papilloma vir | 18004
International Research Journals

Integration event frequency of high-risk human papilloma virus in Mexican women and its association with some risk factors


María E. Cortez-López, Ramón Román-Gámez, Gabriela Meza-Tavares and Ricardo M. Cerda-Flores

Persistent infection with the high-risk human papil loma virus (HR-HPV) has been considered as one necessary factor in the development of cervical ute rine cancer (CUC). One of the processes that seem to be more involved in the origin of malign cells i s the event of the virus integration into the host genome. Consequently, the objectives of this cross- sectional correlational study were: (1) to find out the HR-HPV integration frequency in 216 Mexican women w ith normal cytology; and (2) to correlate having the oncogenic HR-HPV with six factors (ingestion of hormonal contraceptives, number of pregnancies, age, alcohol use, smoking and number of sexual part ners). For this study, 216 samples were analyzed that proved positive to the β ββ β -globin gene via endpoint PCR. Three determinations were carried out: PCR- L1 to determine the presence or absence of HPV; PCR -Nested to confirm the HPV positivity and PCR- LCR to determine the HR-HPV. The two physical virus forms were classified afterwards (integrated and/or episomal). According to molecular analysis, the distribution of results obtained was: 29.63% (64/216) of cases amplified for region L1, and 34.3 7% (22/64) were confirmed with PCR-Nested. Total analysis of samples produced 3.24% (7/216) of oncog enic-positive HR-HPV cases. On revision of the physical condition of the virus in the HR-HPV cases , 0.93% appeared in the integrated form and 2.31% i n the episomal form in the host DNA of the 216 women studied. In conclusion, according to the two objectives, we found that the HR-HPV integration fr equency in 216 Mexican women with normal cytology was 0.93% and that the number of sexual partners wa s the only factor that was associated with women with oncogenic HR-HPV

Share this article